Cypress Consult Capital Management, L.P.
Value inevitably attracts price. We swing big at our best ideas.
Dips and downturns are our double espressos.
When the crowd stampedes left, we advance right — Ignore the crowd.
We are deploying substantial capital into the intersection of biotechnology and artificial intelligence — a generational convergence that we believe will define the next decade of value creation across global markets.
The fusion of AI-driven drug discovery with next-generation genomics is fundamentally compressing the timeline from molecule to medicine. Platforms that once required a decade of bench research are now producing clinical candidates in months. We are identifying and backing the companies building this infrastructure before the market has priced in its full implications.
On the AI side, we look beyond the crowded hyperscaler trade. Our focus falls on the enabling layer: specialized semiconductor architectures, inference optimization platforms, and vertical AI applications where proprietary data creates durable moats. The most asymmetric opportunities are not in the models themselves, but in the companies whose economics are structurally transformed by them.
In biotech, we are particularly attentive to companies leveraging large-scale biological foundation models for protein engineering, gene editing precision, and targeted oncology. The pipeline quality emerging from AI-native biotechs is, in our assessment, materially superior — and still systematically undervalued by a market anchored to legacy drug development timelines.
Capital markets are beginning to recognize this shift. The spread between AI-native life sciences companies and traditional pharma on forward pipeline multiples has widened significantly — and we believe that gap has further to run before consensus catches up to where the science already is.
We are watching closely for regulatory clarity on AI-assisted clinical trial design and the acceleration of FDA review pathways for algorithmically characterized therapeutics — both of which stand to be significant near-term catalysts.
Value inevitably attracts price. We swing big at our best ideas. Dips and downturns are our double espressos. If it's not ridiculously cheap, it's not our cup of tea. And when the crowd stampedes left, we advance right — with courage of conviction.
"In short, we Ignore the crowd." — Cypress Capital Investment Thesis
Global Presence
Nassau, Bahamas
One Montague Place, 1st Floor
East Bay St., P.O. Box N-4906
New Providence
Miami, USA
801 Brickell Ave
Miami, FL 33131
Seattle, USA
Rainier Square, 1301
Fifth Avenue, WA 98101
London, UK
Woolgate Exchange
25 Basinghall Street
London, EC2V 5HA
Wilmington, USA
Corporation Trust Center
1209 Orange St
Wilmington, DE 19804
Legal
None of the information contained in this website constitutes an offer to sell, or a solicitation of an offer to buy or subscribe for, any shares or other securities to the public.
None of the information constitutes an offer in the United States or any other jurisdiction, nor shall it form the basis of any contract or commitment. Shares may not be purchased by an "employee benefit plan" within the meaning of ERISA, including plans subject to Title I of ERISA or Section 4975 of the U.S. Internal Revenue Code.
The Company has not been and will not be registered under the U.S. Investment Company Act of 1940. Shares in the Company have not been and will not be registered under the U.S. Securities Act of 1933. Consequently, shares may not be offered, sold or otherwise transferred within the United States or to U.S. persons as defined in Regulation S, absent registration or an exemption from registration.
The Company is a registered closed-ended investment scheme registered pursuant to the Protection of Investors (Bailiwick of Guernsey) Law, 1987, and the Registered Collective Investment Scheme Rules 2008 issued by the Guernsey Financial Services Commission.
All investment is subject to risk. The value of the shares in the Company may go down as well as up. Past performance is no guarantee of future returns and there is no guarantee that the market price of the Company's shares will fully reflect their underlying net asset value.
There is also no guarantee that the Company's investment objective will be achieved. Potential investors are advised to seek expert financial advice before making any investment decision and should be aware that they may not fully recover the amount invested.
A prospectus has been prepared in connection with the admission of shares in the Company to listing and trading on Euronext in Amsterdam, approved by the Netherlands Authority for the Financial Markets (AFM) on 2 October 2014.
Nothing in this website is, or should be relied on as, a promise or representation as to the future. This website contains forward-looking statements, which reflect the views of the Company and CCM with respect to, among other things, the Company's operations.
Forward-looking statements are subject to various risks, uncertainties and assumptions. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. None of the Company, CCM or any of their respective affiliates undertakes any obligation to update or review any forward-looking statement, except as required by applicable law or regulation.
Copyright of all images and text in this website is owned by or licensed to CCM, the Company or one of their respective affiliates unless otherwise noted. You may imprint, copy, download or temporarily store extracts from this website for your personal information and use.
You may not alter or otherwise make any changes to any material that you print or download from this website, including removing any identifying marks. You may not distribute these materials to others. Any other use is prohibited unless you first request and obtain written permission.
All trademarks, service marks and logos used on this website are trademarks or registered trademarks of either the Company, CCM, their respective affiliates or service providers and should not be copied, altered or abused in any way.
No Reliance: Although CCM has taken all reasonable care to ensure information accuracy, no representation or warranty, expressed or implied, is made as to its accuracy, reliability or completeness. Nothing contained on this website constitutes investment, legal, tax or other advice and is not to be relied on in making any investment or other decision.
No Warranty: The information and opinions contained herein are provided without any warranty of any kind. None of the Company, CCM or any of their respective affiliates assumes any responsibility that information contained on this website will be uninterrupted or error-free.
Liability Waiver: You agree that under no circumstances shall the Company, CCM or any third party be liable for any direct, special or consequential damages that result from the access or use of, or the inability to access or use, the materials on this website. This does not exclude or restrict any duty or liability the Company or CCM has to its customers under the regulatory system in the Netherlands or Guernsey.
This is the Privacy Statement of the Cypress Consult Holdings, Ltd. website. No personal information is requested, collected, required or monitored in respect of access to the site's home page or other pages giving general information about the Company or CCM.
Only limited personal information is required, collected and monitored and then only in respect of the Company. Such personal information will be held and processed in accordance with the Data Protection (Bailiwick of Guernsey) Law, 2001.
The use of the internet to transfer information is not secure. While we do our best to maintain security within our website and to safeguard your personal information, we cannot ensure or warrant the security of any information which you may transmit to us.